QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-equillium-maintains-5-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $5 price target.

 equillium-q2-eps-001-beats-015-estimate-sales-1385m-beat-633m-estimate

Equillium (NASDAQ:EQ) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.15) by 10...

 equillium-announces-interim-analysis-from-phase-3-equator-study-of-itolizumab-in-acute-graft-versus-host-disease

The Independent Data Monitoring Committee (IDMC) recommended continuation of the clinical trial based on safety assessment and ...

 equillium-inc-receives-nasdaq-notice-of-non-compliance-with-listing-rule-5550a2-on-july-19-2024

Minimum Bid Price Below $1.00 For 30 Consecutive Days; No Immediate Effect On Listing; Has Until January 15, 2025 To Regain Com...

 equillium-to-be-included-in-the-russell-microcap-index-effective-at-the-open-of-equity-markets-on-monday-july-1

Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe au...

 hc-wainwright--co-reiterates-buy-on-equillium-maintains-5-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $5 price target.

 nano-cap-equillium-shares-fall-after-patchy-hair-loss-study-data

Equillium released topline data from its Phase 2 study of EQ101 in adult patients with alopecia areata, a disease that results ...

 equillium-announces-topline-data-from-phase-2-study-of-eq101-in-alopecia-areata-20-of-all-subjects-that-completed-the-24-week-treatment-period-achieved-salt--20-eq101-was-well-tolerated-in-subjects-with-alopecia-areata-with-no-serious-adverse-events-reported

20% of all subjects that completed the 24-week treatment period achieved SALT ≤ 2029% of completed subjects with moderate to se...

 hc-wainwright--co-reiterates-buy-on-equillium-maintains-5-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $5 price target.

 hc-wainwright--co-maintains-buy-on-equillium-raises-price-target-to-5

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Equillium (NASDAQ:EQ) with a Buy and raises the price target fr...

 why-westport-fuel-systems-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION